Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.263 CHF
−215.33 M CHF
29.35 M CHF
89.11 M
About Editas Medicine, Inc.
Sector
Industry
CEO
Gilmore O’Neill
Website
Headquarters
Cambridge
Founded
2013
ISIN
US28106W1036
FIGI
BBG00LVD8LB3
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 8EM is 3.345 CHF — it has increased by 193.94% in the past 24 hours. Watch Editas Medicine, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Editas Medicine, Inc. stocks are traded under the ticker 8EM.
We've gathered analysts' opinions on Editas Medicine, Inc. future price: according to them, 8EM price has a max estimate of 4.81 CHF and a min estimate of 0.80 CHF. Watch 8EM chart and read a more detailed Editas Medicine, Inc. stock forecast: see what analysts think of Editas Medicine, Inc. and suggest that you do with its stocks.
8EM stock is 65.98% volatile and has beta coefficient of 2.43. Track Editas Medicine, Inc. stock price on the chart and check out the list of the most volatile stocks — is Editas Medicine, Inc. there?
Today Editas Medicine, Inc. has the market capitalization of 295.08 M, it has increased by 7.25% over the last week.
Yes, you can track Editas Medicine, Inc. financials in yearly and quarterly reports right on TradingView.
Editas Medicine, Inc. is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
8EM earnings for the last quarter are −0.50 CHF per share, whereas the estimation was −0.31 CHF resulting in a −61.31% surprise. The estimated earnings for the next quarter are −0.24 CHF per share. See more details about Editas Medicine, Inc. earnings.
Editas Medicine, Inc. revenue for the last quarter amounts to 2.84 M CHF, despite the estimated figure of 1.83 M CHF. In the next quarter, revenue is expected to reach 3.94 M CHF.
8EM net income for the last quarter is −42.24 M CHF, while the quarter before that showed −67.36 M CHF of net income which accounts for 37.29% change. Track more Editas Medicine, Inc. financial stats to get the full picture.
No, 8EM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 22, 2025, the company has 246 employees. See our rating of the largest employees — is Editas Medicine, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Editas Medicine, Inc. EBITDA is −122.24 M CHF, and current EBITDA margin is −721.39%. See more stats in Editas Medicine, Inc. financial statements.
Like other stocks, 8EM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Editas Medicine, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Editas Medicine, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Editas Medicine, Inc. stock shows the buy signal. See more of Editas Medicine, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.